Heghine Khachatryan: Hemostasis at the Crossroads of Thrombosis and Bleeding
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared Haemophilia Foundation Australia’s post on LinkedIn, adding:
“Hemostasis is far more than the cessation of bleeding – it is a finely regulated biological equilibrium between procoagulant and anticoagulant mechanisms.
Disruption of this balance may manifest as either hemorrhagic complications or thrombotic disease, emphasizing the complexity of modern hemostasis.
Contemporary research increasingly highlights the intimate interplay between coagulation, inflammation, endothelial function, and immune responses, giving rise to the concept of immunothrombosis and reinforcing the multidisciplinary nature of thrombosis research.
These advances continue to reshape diagnostic algorithms, risk stratification, and therapeutic strategies across numerous clinical disciplines.
Continuous scientific collaboration, evidence-based practice, and translational research remain fundamental to improving outcomes for patients with bleeding and thrombotic disorders.”
Haemophilia Foundation Australia shared a post on LinkedIn:
“Currently most gene therapy for haemophilia uses gene transfer.
This involves delivering a functional gene into the body using a vector that carries it into the target cells.
This vector is often a modified virus called adeno-associated virus (AAV) made safe to use.
Once inside the body, the working gene gives instructions to liver cells to produce the missing clotting factor, which may reduce or stop bleeding episodes (‘bleeds’).
Learn more in the new Gene Therapy fact sheet.
Gene therapy is currently only available in Australia through clinical trials.
Gene therapy for haemophilia B is currently being evaluated by the Australian Government for funding to become available for Australians and we look forward to the outcome.”
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering